A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors

被引：0
|
作者：
Laura Q. M. Chow
S. Gail Eckhardt
Cindy L. O’Bryant
Mary Kay Schultz
Mark Morrow
Stacy Grolnic
Michele Basche
Lia Gore
机构：
[1] University of Colorado Cancer Center,
[2] The Children’s Hospital,undefined
[3] University of Colorado Health Sciences Center at Fitzsimons,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2008年 / 62卷
关键词：
Lonafarnib; SCH66336; Cisplatin; Gemcitabine; Farnesyltransferase; Phase I; Pharmacokinetics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：631 / 646
页数：15
相关论文
共 50 条
  • [41] Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors
    Chan, Emily
    Chiorean, E. Gabriela
    O'Dwyer, Peter J.
    Gabrail, Nashat Y.
    Alcindor, Thierry
    Potvin, Diane
    Chao, Richard
    Hurwitz, Herbert
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (02) : 355 - 364
  • [42] Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies
    H. Sayar
    Z. Shen
    S. J. Lee
    M. Royce
    I. Rabinowitz
    F. Lee
    H. Smith
    S. Eberhardt
    A. Maestas
    H. Lu
    C. Verschraegen
    Investigational New Drugs, 2009, 27 : 153 - 158
  • [43] Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer
    R D Kim
    S R Alberts
    C Peña
    I Genvresse
    A Ajavon-Hartmann
    C Xia
    A Kelly
    J E Grilley-Olson
    British Journal of Cancer, 2018, 118 : 462 - 470
  • [44] Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies
    Sayar, H.
    Shen, Z.
    Lee, S. J.
    Royce, M.
    Rabinowitz, I.
    Lee, F.
    Smith, H.
    Eberhardt, S.
    Maestas, A.
    Lu, H.
    Verschraegen, C.
    INVESTIGATIONAL NEW DRUGS, 2009, 27 (02) : 153 - 158
  • [45] Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors
    Doi, Toshihiko
    Yoshino, Takayuki
    Shitara, Kohei
    Matsubara, Nobuaki
    Fuse, Nozomu
    Naito, Yoichi
    Uenaka, Kazunori
    Nakamura, Takashi
    Hynes, Scott M.
    Lin, Aimee Bence
    ANTI-CANCER DRUGS, 2015, 26 (10) : 1043 - 1053
  • [46] Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors
    Caponigro, F.
    Lorusso, D.
    Fornari, G.
    Barone, C.
    Merlano, M.
    Airoldi, M.
    Schena, M.
    MacArthur, R.
    Weitman, S.
    Jannuzzo, M. G.
    Crippa, S.
    Fiorentini, F.
    Petroccione, A.
    Comis, S.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (02) : 389 - 394
  • [47] Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors
    F. Caponigro
    D. Lorusso
    G. Fornari
    C. Barone
    M. Merlano
    M. Airoldi
    M. Schena
    R. MacArthur
    S. Weitman
    M. G. Jannuzzo
    S. Crippa
    F. Fiorentini
    A. Petroccione
    S. Comis
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 389 - 394
  • [48] A phase I pharmacokinetic and pharmacodynamic study of GTI-2040 in combination with gemcitabine in patients with solid tumors
    Laeeq Malik
    Anthony Zwiebel
    James Cooper
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 533 - 539
  • [49] A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)
    Richter, Suzanne
    Bedard, Philippe L.
    Chen, Eric Xueyu
    Clarke, Blaise A.
    Tran, Ben
    Hotte, Sebastien J.
    Stathis, Anastasios
    Hirte, Hal W.
    Razak, Albiruni R. A.
    Reedijk, Michael
    Chen, Zhuo
    Cohen, Brenda
    Zhang, Wen-Jiang
    Wang, Lisa
    Ivy, S. Percy
    Moore, Malcolm J.
    Oza, Amit M.
    Siu, Lillian L.
    McWhirter, Elaine
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (02) : 243 - 249
  • [50] Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours
    Awada, A
    Eskens, FALM
    Piccart, M
    Cutler, DL
    van der Gaast, A
    Bleiberg, H
    Wanders, J
    Faber, MN
    Statkevich, P
    Fumoleau, P
    Verweij, J
    EUROPEAN JOURNAL OF CANCER, 2002, 38 (17) : 2272 - 2278
12345